Introduction
- Pharmacology: Science dealing with drugs.
- Branches:
- Pharmacokinetics: Effect of body on drug.
- Pharmacodynamics: Effect of drug on body.
- Rationale for drug use
- Right drug
- Right dose
- Right disease
- Right patient
- Right duration
- Right route with right dispension and monitoring
- Right price not included
Pharmacokinetics (ADME)
- Absorption
- Distribution
- Metabolism
- Excretion

1. Absorption
- Movement of drug from administration site to blood.
- M/c mechanism: Passive diffusion along the concentration gradient
- Key Factor: Lipid Solubility (most important).
- M/c site : Small intestine
- Poor oral absorption :
- Drugs with large size (Eg : Proteins Drugs with - tide -ase/-mab).
- Drug Absorption based on Medium
Drug Type | Medium | Form | Solubility | Cross |
Acidic | Acidic | Non-ionized | Lipid Soluble | â |
Basic | Basic | Non-ionized | Lipid Soluble | â |
Acidic | Basic | Ionized | Water Soluble | x |
Basic | Acidic | Ionized | Water Soluble | x |
Bioavailability
- Fraction of given dose reaching systemic circulation.

Factors Affecting Bioavailability:
Factor | Effect on Factor | Effect on Bioavailability |
Absorption | â | â |
ă
€ | â | â |
First Pass Metabolism (Pre-systemic metabolism) | â | â |
ă
€ | â | â |
- NOTE: IV route drugs have 100% bioavailability.
- IV > IM/Subcutaneous (~75-100%) > Sublingual/Buccal > Inhalation > Oral > Transdermal
- ViMaL In OT
- VMS IOT
- Transdermal
- Postauricular skin > Scrotal > Armpit= Scalp > Back = Abdomen > Palm = under the surface of the foot.
- E (ear â postauricular) SAAP

Plasma Concentration Vs Time Graph

Description | Feature | Related Parameter |
Rate of absorption | Rate of Absorption | Tmax |
Amount of drug absorbed | Extent of Absorption | AUC |
- Cmax
- Definition: Maximum concentration achieved in plasma
- Clinical relevance:
- Must lie between:
- Minimum Effective Concentration (MEC)
- Maximum Tolerated Concentration (MTC)
- Tmax
- Definition: Time taken to reach Cmax
- Indicates:
- Rate of absorption
Â
AUC (Area Under Curve):

- Total area covered by graph.
- Indicates Extent of absorption
- Aka bioavailability = AUC oral /AUC IV
Bioequivalence:
- 2 drugs are bioequivalent if absorption is within 80 - 125%

2. Distribution
- Amount of drug in tissues after absorption
- Depends on:
- Lipid solubility
- Plasma protein binding (PPB)
Plasma Protein Binding (PPB)
- Acidic drugs â bind to Albumin
- Aspirin
- Anti-coagulant (Warfarin)
- Anti-epileptics/Anti-psychotics/Anti-depressants
- Antibiotics (Sulfonamides)

- Basic drugs â bind to alpha-1 Acid Glycoprotein
- Mnemonic: AA BB TCA O
- Anti-arrhythmics (Amiodarone/Lidocaine)
- b-blockers
- Opioids
- Tricyclic anti-depressants
- High PPB drugs:
- â Volume of Distribution (Vd)
- â Duration of action
- â Drug interactions
- â Filtration
- Dialysis not useful in poisoning
Volume of Distribution (Vd)
- High Volume of distribution
- â extravascular concentration.
- More drug is present in the tissues
- â clearance on dialysis
- Drugs with â Vd (BAD DOC):
- CHLOROQUINE
- Bulls eye maculopathy
- Conea verticillata
- Erythema multiforme
- Benzodiazepine
- Amphetamines
- Digoxin
- Opioids
- Cyclic antidepressants
- Low Volume of distribution
- â intravascular concentration.
- Formula:
- Vd = Amount of drug given IV / Plasma concentration
- Vd = CL/kE
- Interpretation:
- Vd â Amount of drug in tissues
- Mnemonic:Â ViDeo = DOwnloader/CONverter
- Vd = Dose via IV route (Loading dose)/ Initial PC
- E.g. To achieve a target Cp of 1.5 ”g/L for digoxin (Vd = 500 L)
- LD (”g) = 500 (L) X 1.5 (”g/L) = 750 ”g
- Mnemonic:Â ViDeo = CLear/KlEar
- Vd = CL/kE
- E.g. A 2,000 mg dose with a concentration of 600 mg/L has a clearance of 0.05 L/hr. What is the elimination rate constant (KE)?
- Vd = CL/kE = 0.05/kE
- Also, Vd = D/Co = 2000/600
- i.e. 0.05/kE = 2000/600
- kE = 0.05 X 600/2000 = 0.015 hr

Loading Dose (LD)
- Formula:
- LD = Vd Ă Target Plasma Concentration
Bioavailability
Maintenance Dose (MD)
- Formula:
- MD = Clearance (CL) Ă Target Plasma Concentration
Bioavailability - Maintenance dose = Dosing rate X Dosing interval
- Volume of distribution for loading dose.
- Clearance for maintenance dose.
- Clearance
- Body's ability to eliminate the drug from the body
Maintenance dose calculation:
Clearance of theophylline is 2.8 L/hr and Target concentration is 10 mg/L. What is the TDS maintenance dose?
- Maintenance dose = Dosing rate X Dosing interval
= Dosing rate X 8
- Dosing rate = CL X Target concentration = 2.8 X 10 = 28 mg/hr
- Maintenance dose = Dosing rate X 8 = 28 X 8 = 224 mg
- If the bio-availability is <1, divide by bioavailability (F). Suppose, if the bioavailability of theophylline is 0.8. Then,
- Maintenance dose = 224/0.8 = 280 mg
In renal or liver disease
- maintenance dose is decreased
- loading dose is usually unchanged.
3. Metabolism


Aim:
- 1st aim â To make a drug water-soluble (Polar).
- 2nd â To convert to active metabolite
Prodrugs :
- Proguanil.
- Ramipril & other ACEi (except Captopril, Lisinopril).
- Oxcarbazepine
- Omeprazole.
- Dipivefrine
- Levodopa.
- Racecadotril.
- 5- Fluorouracil.
- Capecitabin
- Gemcitabine.
- Phenyl butyrate
- Fluticasone
- Carbimazole (Prodrug) â Methimazole (Active)
- Latanoprostene bunod (Prodrug)
- breaks down into â Latanoprost + Butadenol (Unstable)
- Sulfasalazine
- Mycophenolate
- Acyclovir/ Gancyclovir
- Enzymes
- Microsomal:
- Present in smooth endoplasmic reticulum.
- Can be induced or inhibited.
- Mic (Microsomal ) ilu glucose(Glucornidation) is smooth (SER) and can adjust the volume (induced or inhibited)
- Non-microsomal:
- Present outside SER.
- Cannot be induced or inhibited.
Â
Which one of the following drugs does not undergo acetylation metabolism?
A. Isoniazid
B. Hydralazine
C. Phenytoin
D. Procainamide
A. Isoniazid
B. Hydralazine
C. Phenytoin
D. Procainamide

Cytochrome P450 Enzymes (CYPs):
- Microsomal enzymes.
- CYP3A4Â (m/c):
- Cyclosporine
- Tacrolimus
- Statins
- Cisapride, Astemizole, Terfenadine (CAT)
- CAT cute â QT prolongation
- Amiodarone
- Navirs

- Mnemonic: CT Scan
- CYP2D6Â drugs:
- Beta-blockers
- Anti-depressants
- Anti-arrhythmics
- (except Amiodarone)
- Opioids
- TAMOXIFEN â active
- Mnemonic: 2D6
- 2 â Beta
- D â Depressant
- 6 â Sex â Antiarrythmic
- CYP2C19Â drugs:
- Activates Clopidogrel
- Metabolises Omeprazole
- Competitive inhibitors
- 2 substrates 1 enzyme
- Omeprazole â â Clopidogrel effect â PPIs avoided with clopidogrel
- CYP2C9Â drugs:
- Warfarin
- Phenytoin
- Benzbromozone (Suicidal inhibition)
- Mnemonic:
- C â Coagulant â warfarin
- 9 â P â Phenytoin
P450 Enzyme Inhibitors (SICK FACES.COM) | P450 Enzyme Inducers (CRAP GPS) |
â enzyme â â metabolism â â Plasma concentration â Drug toxicity Inhibit â Sick when toxic + ADD Grape | â enzyme â â metabolism â â Plasma concentration â Drug failure Induce â Crap the drugs â drug failure |
Sodium Valproate Isoniazid Cimetidine Ketoconazole Fluconazole Alcohol (Acute) Chloramphenicol Erythromycin, Clarithromycin (Not Azithromycin) Sulfonamides Ciprofloxacin Omeprazole Metronidazole **Disulfiram, Allopurinol Grapefruit juice Diethylcarbamazine | Carbamazepine Rifampicin Alcohol (Chronic) Phenytoin Griseofulvin Phenobarbital Sulphonylureas St Johnâs wart (Plant used to treat depression) |
Effect: â Warfarin effect (âŹINR) | Effect: â Warfarin effect (âŹINR) |
With COCP: âą No change needed | With COCP: âą Requires additional contraceptive âą e.g., Depo-Provera, IUS, barrier methods |
Erythromycin â Theophylline toxicity (VT, VF) | ă
€ |
Clarithromycin â Statin toxicity | ă
€ |
- All Antibiotics except Griseofulvin (Inducer)
- Are Inhibitors
- CYP â and QT ââ
- Ketoconazole
- Ciprofloxacin
- Erythromycin
CYP3A4 Inhibitors: N â Navir, Nazole | CYP3A4 Substrates: Substrate toxicity when given with Inhibitors Remember CT Scan |
Ritonavir (boost other antivirals) | Saquinavir |
Voriconazole | Amlodipine |
Itraconazole | Atorvastatin |
Verapamil/ Diltiazem | Midazolam |
Erythromycin | Sildenafil |
Grapefruit juice | Tacrolimus |
4. Excretion

Glomerular Filtration
- Filters:
- Both lipid-soluble and water-soluble drugs
- Filtration â with:
- â Plasma Protein Binding
Tubular Reabsorption
- 99% of GFR is reabsorbed
- Lipid-soluble drugs:
- Reabsorbed back
- Example (in poisoning):
- Aspirin, barbiturates (acidic drugs)
- Urine alkalinisation with bicarbonate â prevents reabsorption
- Water-soluble drugs:
- Remain in urine â excreted
Tubular Secretion
- Occurs in proximal tubule
- Active transport via saturable pumps/transporters
Note
- Probenecid:
- âpenicillin secretion â Prolong action
- Aspirin
- â Uricosuric action of Probenecid
Enzymes
Classification of Receptors





ă
€ | Type | Speed of Action | Description |
1 | Ionotropic Receptors | Fastest acting âł (in CNS) | âą Receptors on ion channels Examples âą GABA-A, NMDA, NN, NM, 5HT3 |
2 | Enzymatic Receptors | Slow | âą Aka Tyrosine Kinase Receptors âą Cell membrane, intracellular & extracellular ends. âą Drug binds outside, activates intracellular enzyme. Examples âą Cytokines, Prolactin, Insulin, GH |
3 | GPCR | Moderate | âą Work via cAMP, Ca2+, or ion channels opening. Examples âą Most other receptors |
4 | Intracellular Receptors | Slowest acting | âą Cytoplasmic or Nuclear. âą Only lipid-soluble drugs. âą Work through DNA (nuclear mechanism). Examples âą Cytoplasmic: âł Vit D, Glucocorticoids, Mineralocorticoids âą Nuclear: âł Vit A, Thyroid hormones, Sex hormones. |
- GPCR G-Protein Types:
Type | Mechanism | Second/Third Messenger |
Gs | Stimulate adenylate cyclase | â cAMP â Activate Protein Kinase A |
Gi | Inhibit adenylate cyclase | â cAMP |
Gq | Convert PIP2 to IP3 and DAG | IP3, DAG â ââ Calcium (intracellular) |
Classification of Drugs
Pregnancy Categories
- Drugs categorized into 5 groups based on safety in pregnancy:
- Category A: Safest.
- Category B
- Category C
- Category D: Can be given in pregnancy, if benefit>risk (Valproate)
- Category X: Contra-indicated in pregnancy (e.g., Thalidomide).
- Mnemonic: C X â Carrying No
- Note:
- Schedule X drugs:
- Narcotic and psychotropic drugs (e.g., Ketamine).
- Different from Category X.
- Mnemonic: S X â Sex and Narcotics
- Schedule H drugs:
- Require prescription
- Prescription/legend drugs
- Mnemonic: H â from Hospitals
Safe and Unsafe Drugs in Pregnancy
Condition | Safe in Pregnancy | Avoid/Contra-indicated in Pregnancy |
Hypertension | Labetalol, Methyldopa | ACE Inhibitors, ARBs |
Anticoagulants | Heparin | Warfarin |
Bipolar Disorders | Anti-psychotics | Valproate (contra-indicated), Lithium (avoid) |
Anti-thyroid | Propylthiouracil | Carbimazole (1st trimester) âł Aplasia Cutis âł Choanal atresia |
Anti-microbials | Penicillins, Cephalosporins, Macrolides | Tetracyclines (teeth and bone), Quinolones (cartilage or tendon) Aminoglycosides (hearing loss) |
Anti-Epileptics | Levetiracetam, Lamotrigine Mnemonic: LL â Least toxic | Valproate Mnemonic: Very toxic |
P Medicines and STEP Criteria
- P medicines = Physicianâs drugs / Personal drugs
- Regularly prescribed by a doctor for common conditions
- Doctor is well-versed with:
- Drug name
- Dosage
- Schedule
- Duration of use
- Indication for the ailment
STEP Criteria
- S.T.E.P. is an acronym used for selecting P medicines:
- S â Safety of the medication
- T â Tolerability
- E â Effectiveness
- P â Price / Cost of the drug
Steps in Choosing a P Medicine
- Describe the medical diagnosis
- State the therapeutic goal
- List effective medicine groups
- Use STEP criteria to choose best group
- Select a specific P medicine from the group
Types of Drugs
Orphan drugs:
- Rare diseases
- â Profitability
- â Development
- Some of the orphan drugs include:
- clofazimine,
- carboprost,
- rifaximin,
- rituximab
- busulfan.
NOTE: Orphan receptors
- Receptors with no known endogenous mediator or ligand.
Essential drugs:
- Inexpensive.
- Non-toxic.
- Easily available.
- Efficacious.
- Safe.
- Single molecule (Not fixed dose combination).
The Drugs and Cosmetics Act
- Regulates import, manufacture, distribution, and sale of drugs.
Medical products | Meaning |
Misbranded Drug/ Counterfeit | âą Intentionally made to deceive. âą Not labelled correctly, or label makes false claims. âą A drug stating 500mg of paracetamol per tablet but containing only 200mg is a misbranded drug. |
Sub-standard/ Out of specification | âą Authorized medical products that do not meet quality standards. |
Falsified/ Spurious Drug | âą Deliberately misrepresent identity or source of composition. âą Imitation or substitute, deceptive name âą (e.g., small company imitating known brand). âą Punishable: Life Imprisonment âą Furious â Imprison for life âą North indian companies making fake branded products |
Unregistered | âą Not evaluated or approved. |
Adulterated Drug | âą Contains filthy, putrid, or decomposed substances. |

Enteric Coating of Drugs
- Coating dissolves only in alkaline medium.
- Uses:
- Protects acid-labile drugs from gastric acid (e.g., Proton Pump Inhibitors).
- Protects gastric mucosa from irritant drugs (e.g., NSAIDs).
- Increases absorption of drugs absorbed distally to stomach.
Uses of controlled/sustained release :

- â Duration of effect
- â no. of doses (Useful if t1/2/< 4h)
- â Risk of acute toxicity :
- D/t lower/absent peak concentration.
Fixed Dose Combinations (FDC)
- Two or more drugs combined in a specific ratio.
- Advantages:
- Improved compliance.
- One drug may reduce adverse effects of another.
- Increased efficacy.
- Reduced cost.
- Disadvantages:
- May lead to irrational use.
- Difficult to ascribe adverse effects to a single drug.
- Cannot combine drugs with different pharmacokinetics.
- Individual drug dose cannot be altered independently.
Prescription Writing

- Written order from doctor to pharmacist to dispense medication.
- Essentials:
- Must include date and signature (or initials) for validity.
- Dos and Don'ts:
- Drug name: Never in short form (e.g., write "paracetamol," not "PCM").
- Abbreviations: Do not use OD, BD, HS.
- Dose Notation:
- Leading zeros: Always mentioned (e.g., 0.5 mg, not .5 mg).
- Trailing zeros: Never mentioned (e.g., 5 mg, not 5.0 mg).
- Units: Microgram should be written as mcg, not Όg.
Schedule | Details | ă
€ |
Schedule C | Biological and other special products e.g. Toxins, Insulin, Sera & Antibiotics | C â Covid â Vaccine |
Schedule D | List of drugs exempted from the provision of import of drugs. | D â Drug Import |
Schedule F | Blood and blood products | F â Fucking blood |
ă
€ | F I - Production of Bacterial vaccines, Anti-Sera | ă
€ |
ă
€ | F II - Specification of standards for Surgical dressing | ă
€ |
ă
€ | FF - Specification of standard Ophthalmic preparation | ă
€ |
Schedule G | With a label of Caution, dangerous to use except Under medical supervision. | G â Gee â leave me alone |
Schedule H | Prescription drugs. Eg: Halothane, thalidomide | H â Hospital presciption |
Schedule J | Cannot be treated Eg - HIV & Atherosclerosis | J â Jay cannot be treated |
Schedule M | Regulations regarding good manufacturing practices | M â Manufacturing good |
Schedule P | Regulations regarding the life period and storage of various drugs. Eg: Colistin | P â Period |
Schedule W | Drugs marketed under generic names. | ă
€ |
Schedule X | Drugs having abuse and dependence liability. Eg: Ketamine, Thalidomide | SX â Sex and Nacrotics |
Schedule Y | Requirement and guidelines for import/ manufacture or Clinical trials in India | Y import |
Temperature Definitions
General Temperature Ranges
- Excessively hot:
- > 40 °C
- Warm:
- 30 - 40 °C
- Room temperature:
- Average temperature in a workspace
- Cool:
- 8 to 25 °C
P-glycoprotein (Pgp) and MDR1 Pump

Active Transport
- Most common type of ABC pump (ATP-Binding Cassette transporter)
Function of P-glycoprotein (Pgp) Pump
- Small intestine, liver
- Clinical relevance:
- Digoxin dosage is adjusted based on loss via efflux

- Blood-Brain Barrier (BBB)
- Example: Loperamide
- Does not cross BBB due to:
- MDR1 efflux
- Water solubility

- Placenta
- Restricts maternal-to-fetal drug transfer
- Bile Acid Excretion
- Mediate bile acid and drug excretion
- In Bacteria / Tumor Cells
- Leads to:
- Drug efflux
- Drug resistance
Pharmacological Significance of P-glycoprotein
Category | Examples | Clinical Outcome | Effect on Pump |
Inducers | âą Rifampicin âą Phenytoin âą Carbamazepine | Drug failure | Increase pump number |
Inhibitors | CAVE Q âą Cyclosporine âą Amiodarone âą Verapamil âą Erythromycin / Clarithromycin âą Quinidine âą Itraconazole âą Neratinib | Drug toxicity | Decrease pump number |
Substrate | âą Loperamide (BBB) âą Digoxin (Intestine) | â | Undergoes efflux by pump |
ABC Terms | Seen in |
ABCG2 | âą Marker for Limbus/Pterygium (with CD34) |
ABCA4 gene mutation | Stargardt Disease âą Juvenile boy (Juvenile hereditary macular dystrophy) âą Star (stargardts) â studies ABC (ABCA4 gene mutation) ⊠At night (bcz blind during day â Hemeralopia) âą Eat fish (fish flecks) & bulls eye (Bulls eye maculopathy) âą Everyone beat him (copper beaten on Fundus exam) ⊠Became Dark & Silent (dark/silent choroidal sign on FFA) |
ABC1 (ATP Binding Cassette transporter 1) Mutation | Tangier's Disease âą Reduced levels of apo A1â very low HDL levels âą Features âą Greyish-orange tonsils âą Hepatosplenomegaly âą Mononeuritis multiplex âą ABC students drink Tang â don't get A1 â cant multiply |
ABCC2 gene mutation / MRP2 protein | Dubin Johnson Syndrome âą Dark pigmented liver âą Pigment is epinephrine Dubbing Johnson âą Dubin is dark âą A busy (ABC) dubbing artist âą needs MRP (MRP2) |
ABC Pump | âą Digoxin dosage is adjusted based on loss via efflux (GI) âą Loperamide does not cross BBB (no CNS S/E) âą Bacteria / Tumor Cells: Drug resistance |
ABC Pump Inducer (CRP in CRAP GPs) | Cause Drug Failure |
âł Rifampicin | Digoxin failure |
âł Phenytoin | ă
€ |
âł Carbamazepine | ă
€ |
ABC Pump Inhibitor (CAVE Q itra neram) | Cause Toxicity |
âł Cyclosporine | Cholestatic jaundice |
âł Amiodarone | ă
€ |
âł Verapamil | Reversal of drug resistance âł Verapamil â Vera kalayan â Bacteria kalayan âą (cancer, bacteria) |
âł Erythromycin / Clarithromycin | Digoxin toxicity |
âł Quinidine | Loperamide-induced central S/E |
âł Itraconazole | ă
€ |
âł Neratinib | ă
€ |
Pharmacodynamics
Agonists


Classification of Drugs (by Intrinsic Activity)
Drug Type | Intrinsic Activity | Action |
Agonist | Maximum (+1) | Produces full biological response |
Partial Agonist | Submaximum (0 to 1) | Produces partial response, even at full receptor occupancy Can act at the same site as a full agonist. |
Antagonist | No action itself (0) | Interferes with action of other drugs |
Inverse Agonist | Opposite action (-) | Produces effects opposite to agonists |

Mixed Agonist/Antagonist:
ÎŒ & Îș

- Morphine â More ÎŒ & Îș + â Morphine more (ÎŒ & Îș )
- Pentazocine â Partial ÎŒ & Îș +
- Buprenorphine â bU â ÎŒ â Partial ÎŒ, Antagonist at Îș
Generic Name | ÎŒ | Îș |
Morphine | ++ | ++ |
Buprenorphine | ± | - |
Pentazocine | ± | ++ |
- +++: Strong agonist
- ±: Partial or weak agonist
- - : Antagonist
Â
- Agonists at one opioid receptor subtype (Îș) and
- partial agonists/antagonists at another (Ό).
- Cause less respiratory depression than full opioid agonists.
- Can cause less opioid withdrawal symptoms than full opioid agonists.
- Not easily reversed with Naloxone.
Other Types of Antagonism
Type | Definition | Examples |
Physical/ Pharmacokinetic Antagonism | Antagonism due to physical binding of antagonist | Charcoal in alcohol toxicity â Adsorbs alcohol â Prevents absorption |
Chemical Antagonism | Antagonism via chemical reaction | Heparin (âve) + Protamine sulphate (+ve) Iron + Desferrioxamine (chelation) |
Physiological Antagonism | Antagonism via opposite effect at different receptors | Histamine via H1 receptor â Bronchoconstriction Antagonized by bronchodilator acting via different receptor |
Suicide Inhibition
- Definition:
- Unreactive substrate analogue binds to active site of enzyme
- Modified by the enzyme â produce reactive group â reacts irreversibly â
- Form covalent bond â form stable inhibitor-enzyme complex
- Suicide Inhibitors are unreactive until within the enzyme's active site.
- Examples:
- Mnemonic: Santhaclose () cycleil () Pii Pii (PI) vannapo â odichu (ornithine) â Benzill (Benzbromozone) â Return (Retonavir) varan paranju
Inhibitor | Enzyme Targeted |
Allopurinol | Xanthine oxidase |
Difluoromethyl ornithine | Ornithine decarboxylase |
Aspirin | Cyclooxygenase |
Benzbromozone | CYP2C9 |
MAO inhibitors | Phenelzine |
PPIs | ă
€ |
Retonavir | PI |
Hit and Run
- PPI

Log Dose Response Curve (Log DRC)
- S-shaped (Sigmoid Curve)
- clinically useful

Log D â Log dose

Â
- Potency: curve for A is left of B
- X axis; P â Pettannu
- â A has lower EC50
- â A is more potent
- Efficacy:
- Y axis â Efficacy â hEight
- A and B reach the same
- Both has same efficacy
Provides 3 parameters:

Â

1. Potency
- Definition:
- Lower dose needed to produce same effect â More potent
- Graph:
- Left-shifted curve = Higher potency
- D>A>C>B>D
2. Efficacy
- Definition: Maximum effect achievable regardless of dose
- Graph:
- Higher curve (Y-axis) = Greater efficacy
3. Slope
- Indicates: Magnitude of effect with dose change
- Steeper slope â Dangerous
Quantal Dose-Response Curve

- Used for "All or None" phenomena
â Response cannot be graded
- Measures variation in drug responsiveness to a fixed dose across individuals
Axes and Interpretation
- Y-axis: % of subjects responding
- X-axis: Drug dose
- Represents effect in a population
Key Terms
- LDâ â: Dose lethal to 50% of animal population
- EDâ â: Dose effective in 50% of population.
- TDâ â: Dose producing toxicity in 50% of human population
- Used instead of LDâ â in humans
Therapeutic Index (TI)
- Mnemonic: TILE
- Formula:
- Classical (Animal studies):
- TI = LDâ â / EDâ â
- Human (Clinical use):
- TI = TDâ â / EDâ â
- Indicates the margin of safety of a drug
- Higher TI = Safer drug
- Eg: Penicillin.
- Lower TI = unsafe
- Eg: Digoxin, Lithium, Theophylline, Warfarin, Gentamicin
Therapeutic window
- Area between the dotted lines
- It is the range of steady-state concentrations of a drug that provides therapeutic efficacy with minimal toxicity.

Therapeutic Drug Monitoring (TDM)
- Mneumonic: DAT LAAT MC
TDM Drugs |
Digoxin |
Aminoglycosides |
Theophylline |
Lithium |
Anti arrhythmics |
Antiepileptic (Phenytoin ) |
Antidepressants (TCA) |
Methotrexate |
Calcineurin Inhibitor |